Why the study?
Does clopidogrel prevent ischaemic cardiovascular events in patients requiring secondary prevention?
Population
Patients requiring secondary prevention of broad ischaemic cardiovascular events
Design
Review
Authors
Loading...
Supports Phase III trials in secondary prevention; leaves open ischaemic event reduction beyond aspirin.
Does clopidogrel prevent ischaemic cardiovascular events in patients requiring secondary prevention?
Clopidogrel is a promising novel antiplatelet agent expected to reduce cardiovascular morbidity and mortality beyond currently available therapies.
Feuerstein et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: